| Literature DB >> 25443235 |
Muhammad Rizwan Sardar1, Wajeeha Saeed2, Peter R Kowey3.
Abstract
Atrial fibrillation (AF) is the most frequently encountered arrhythmia. Prevalence increases with advancing age and so as its associated comorbidities, like heart failure. Choice of pharmacologic therapy depends on whether the goal of treatment is maintaining sinus rhythm or tolerating AF with adequate control of ventricular rates. Antiarrhythmic therapy and conversion of AF into sinus rhythm comes with the side effect profile, and we should select best antiarrhythmic therapy, individualized to the patient. New antiarrhythmic drugs are being tested in clinical trials. Drugs that target remodeling and inflammation are being tested for their use as prevention of AF or as upstream therapy.Entities:
Keywords: Antiarrhythmic; Atrial fibrillation; Cardioversion; Pharmacologic therapy; Prevention; Rate control; Rhythm control; Upstream therapy
Mesh:
Substances:
Year: 2014 PMID: 25443235 DOI: 10.1016/j.ccl.2014.07.012
Source DB: PubMed Journal: Cardiol Clin ISSN: 0733-8651 Impact factor: 2.213